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Double Trouble
Flu Intensifies Effects of Ozone
Environmental health scientists have long speculated that the influ-
enza virus could intensify the pulmonary effects of air pollution or 
vice versa. Like air pollution, influenza affects primarily the respiratory 
system, and ambient air pollutants may either lower resistance to viral 
infection or provide a vehicle that facilitates the spread of the virus, or 
both. There have been a number of laboratory-based animal studies on 
this potential relationship but no epidemiologic research. Researchers 
at the University of Hong Kong, in the first study of the influenza–air 
pollution interaction in humans, now report that respiratory hospital-
izations and mortality significantly increased when ozone (O3) levels 
rose during flu season [EHP 117:248–253; Wong et al.].
The  authors  conducted  a 
retro  spective population-based 
study focusing on hospitalization 
and mortality rates for respira-
tory and cardiovascular disease. 
Medical data on patients diag-
nosed with respiratory or cardio-
vascular disease between 1996 and 
2002 came from 14 Hong Kong 
hospitals. The authors determined 
“influenza intensity” during the 
same period as the percentage of 
respiratory specimens that tested 
positive for influenza each week. 
The Hong Kong Environmental 
Protection Department provided 
data on average daily concentra-
tions of nitrogen dioxide (NO2), 
sulfur dioxide (SO2), particu-
late matter smaller than 10 µm 
(PM10), and O3. 
As O3 levels increased during times of high influenza inten-
sity, so did the number of hospitalizations and deaths from respira-
tory disease. The association was stronger in women than men, the 
researchers reported. There was no significant relationship between 
O3 and cardiovascular disease hospitalizations or mortality, and the 
data reflected no significant modification by influenza on the health 
effects of the other pollutants studied. Hong Kong has two flu sea-
sons, peaking in January–February and May–July. O3 levels in Hong 
Kong typically peak in the sunniest months of September–December, 
when ultraviolet radiation reacts with nitrogen oxides and volatile 
organic compounds to form the noxious gas.
A surprising finding was a decrease in hospitalization for respi-
ratory illness when peak PM10 concentrations coincided with flu 
outbreaks, whereas PM10 increases at other times were associated 
with increased hospitalizations. 
The  researchers  hypothesize 
that PM10 may diminish the flu 
effect by limiting the amount 
of ultraviolet light entering 
the atmosphere, which in turn 
would reduce the production 
of ozone. 
The  authors  found  weak 
interactions between influenza 
and both NO2 and SO2, but cau-
tioned against drawing conclu-
sions about individual pollutants 
that react in the atmosphere. 
NO2, for example, can combine 
with oxygen to form O3. The 
researchers propose that future 
studies  focus  on  influ  enza’s 
potential  interactions  with  a 
combination of pollutants in the 
atmosphere. –Cynthia Washam
Environews | Science Selections
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Phthalates in Prescription Drugs
Some Medications Deliver High Doses 
Until recently, most of the concern surrounding the health risks 
of phthalates has focused on the use of these plasticizers in toys, 
personal care products, food packaging, and medical equip-
ment such as intravenous tubing. A case report in 2004 raised 
the possibility that certain prescription medications may also be a 
source of phthalate exposure for some people [EHP 112:751–753 
(2004)]. That finding prompted a systematic investigation that 
links phthalate-containing medications with high internal exposure 
to these chemicals [EHP 117:185–189; Hernández-Díaz et al.]. 
The 2004 case study pinpointed Asacol®, a medication for 
treating ulcerative colitis, as a probable source of phthalate exposure. 
Asacol is covered with an enteric coating of dibutyl phthalate (DBP) 
that prevents the medication from degrading before it reaches the 
small intestine. Concentrations of the main metabolite of DBP in 
the urine of the case study subject corresponded to an uptake of DBP 
exceeding by two orders of magnitude the 95th percentile reported 
by the Centers for Disease Control and Prevention in the gen-
eral population. The concentrations also surpassed the reference dose 
established for DBP by the U.S. Environmental Protection Agency 
(EPA) on the basis of animal testing. 
To assess possible links between phthalate-containing prescription 
medication usage and excreted metabolites, the investigators searched 
National Health and Nutrition Examination Survey (NHANES) 
data from survey periods between 1999 and 2004 when urine 
samples were tested for phthalate metabolites and participants were 
asked about their use of prescription medications. Various enteric-
coated medications identified as likely to contain phthalates included 
mesalamine (the generic form of Asacol), didanosine (an antiretro-
viral agent), omeprazole (which inhibits gastric acid secretion), and 
theophylline (used to treat asthma and other lung diseases). 
Among the 6 documented mesalamine users, average urine 
concentrations of DBP metabolites were 50 times higher than those 
of nonusers. For 2 of the 6 mesalamine users, the DBP metabolite 
concentrations pointed to uptake exceeding the EPA’s reference dose. 
Users of the other phthalate-containing medications also had signifi-
cantly higher concentrations of some metabolites than did nonusers, 
though the gaps between users and nonusers were considerably 
smaller than for mesalamine. The NHANES data also showed that at 
least 3 women who reported taking phthalate-containing medications 
were pregnant. 
These findings call for more investigation, the authors write, par-
ticularly because some phthalates cross the placenta and cause repro-
ductive and developmental effects in laboratory animals. In one study 
of male infants, increasing prenatal exposure to background levels of 
phthalates was associated with a decrease in the distance between the 
anus and base of the penis, indicating incomplete male reproductive 
development [EHP 113:1056–1061 (2005)]. The authors of the 
new study write that phthalate-containing medications are among 
some of the most widely prescribed drugs in the United States, 
which implies that many people, including pregnant women, may be 
exposed to high concentrations of phthalates. –Kellyn S. Betts
Influenza appeared to 
exacerbate the health effects of 
ozone pollution in Hong Kong.Trumped Treatment?
BPA Blocks Effects of Breast Cancer 
Chemotherapy Drugs
Widespread human exposure to the chemical bisphenol A (BPA) has 
resulted from its use in a diverse array of consumer products. Research 
on the potential health effects of BPA has focused on the chemical’s 
ability to mimic or block natural estrogen. In animal studies, prenatal 
exposure to BPA increased sus-
ceptibility to mammary cancer 
in adulthood. However, studies 
of adult animals and cell cultures 
have had mixed results, and even 
less certain is how BPA might 
influence established breast can-
cer and its treatment. A new cell 
culture study is the first to show 
that  BPA,  at  concentrations 
comparable to those found in the 
general population, reduces the 
efficacy of chemotherapy drugs 
in breast cancer cells, appar-
ently by altering expression of 
proteins involved in apoptosis, 
or programmed cell death [EHP 
117:175–180; LaPensee et al.].
The study used estrogen-
responsive T47D cells and estro-
gen-insensitive MDA-MB-468 
cells. Cells were pretreated with BPA and then incubated alone or 
with one of several concentrations of added doxorubicin, cisplatin, 
or vinblastine, commonly used chemotherapy drugs. BPA concen-
trations (1 and 10 nM) were comparable to levels documented in 
human milk and blood (0.5–40 nM). In some experiments, BPA 
pretreatment was preceded by addition of either ICI or PHTPP, 
compounds that block classical estrogen receptor-α and -β (ERα 
and ERβ, respectively). In addition to assessing cell survival, the 
researchers determined genetic expression and concentrations of the 
antiapoptotic proteins Bcl-2, Bcl-xL, and survivin, as well as classical 
and nonclassical estrogen receptors.
The researchers found in T47D cells that BPA partially or 
completely blocked the effects of all doses of doxorubicin and cis-
platin but only the lowest dose of vinblastine, with similar results 
in MDA-MB-468 cells. BPA by itself bolstered cell viability (i.e., 
chemoresistance) in T47D cells 
but not in MDA-MB-468 cells. 
Neither ICI nor PHTPP affect-
ed the ability of BPA to block 
doxorubicin’s actions in T47D 
cells, and BPA was able to medi-
ate the drugs’ effects in MDA-
MB-468 cells. These observa-
tions together suggest that BPA 
does not act via ERα or ERβ, 
helping to account for its effects 
on ER-insensitive cells. 
Given  previous  research 
that demonstrates a high bind-
ing affinity of estrogen-related 
receptor-γ  (ERRγ)  to  BPA 
[EHP 116:32–38 (2008)], the 
researchers speculate that ERRγ, 
expressed by both cell lines in 
their study, is the most likely tar-
get for BPA binding. Based on 
their finding that BPA combined with doxorubicin increased levels of 
Bcl-2 and Bcl-xL, the researchers conclude that derailment of apop-
tosis could be a mechanism—perhaps common to all three drugs—
by which BPA may inhibit the efficacy of breast cancer drugs. Both 
BPA binding to ERRγ and the compound’s role in apoptosis should 
be further examined in future research. –Julia R. Barrett
Science Selections
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Bisphenol A prevented 
chemotherapy drugs 
from inducing apoptosis 
in cultured breast 
cancer cells.